RANI vs. VYGR, LFVN, ITOS, AQST, YMAB, IMMP, OLMA, ATYR, RZLT, and NGNE
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), Y-mAbs Therapeutics (YMAB), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Atyr PHARMA (ATYR), Rezolute (RZLT), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry.
Rani Therapeutics vs.
Rani Therapeutics (NASDAQ:RANI) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 53.3% of Rani Therapeutics shares are held by insiders. Comparatively, 4.5% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Voyager Therapeutics received 362 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 81.58% of users gave Rani Therapeutics an outperform vote while only 67.64% of users gave Voyager Therapeutics an outperform vote.
Rani Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
In the previous week, Voyager Therapeutics had 6 more articles in the media than Rani Therapeutics. MarketBeat recorded 10 mentions for Voyager Therapeutics and 4 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.77 beat Voyager Therapeutics' score of 0.67 indicating that Rani Therapeutics is being referred to more favorably in the media.
Rani Therapeutics presently has a consensus target price of $11.71, suggesting a potential upside of 794.22%. Voyager Therapeutics has a consensus target price of $15.97, suggesting a potential upside of 214.92%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rani Therapeutics is more favorable than Voyager Therapeutics.
Voyager Therapeutics has a net margin of 15.80% compared to Rani Therapeutics' net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Rani Therapeutics' return on equity.
Voyager Therapeutics has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Voyager Therapeutics beats Rani Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rani Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RANI) was last updated on 1/20/2025 by MarketBeat.com Staff
